Seer Inc
NASDAQ:SEER

Watchlist Manager
Seer Inc Logo
Seer Inc
NASDAQ:SEER
Watchlist
Price: 2.43 USD 2.1% Market Closed
Market Cap: 143.3m USD
Have any thoughts about
Seer Inc?
Write Note

Seer Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Seer Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Seer Inc
NASDAQ:SEER
Accrued Liabilities
$11.5m
CAGR 3-Years
28%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Accrued Liabilities
$5.2B
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
12%
Danaher Corp
NYSE:DHR
Accrued Liabilities
$2.9B
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
1%
Mettler-Toledo International Inc
NYSE:MTD
Accrued Liabilities
$364.6m
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Accrued Liabilities
$573m
CAGR 3-Years
-8%
CAGR 5-Years
5%
CAGR 10-Years
-2%
IQVIA Holdings Inc
NYSE:IQV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Seer Inc
Glance View

Market Cap
144.8m USD
Industry
Life Sciences Tools & Services

Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. The company is headquartered in Redwood City, California and currently employs 118 full-time employees. The company went IPO on 2020-12-04. The firm enables scientific outcomes by commercializing products for researchers to unlock biological information. Its initial product, the Proteograph Product Suite (Proteograph), uses its engineered nanoparticle (NP) technology to provide access across the proteome. Its Proteograph Product Suite is comprised of consumables, an automation instrument and software. Its Proteograph provides a workflow, which enables proteomic profiling and the analysis of samples needed to characterize the nature of the proteome. The Company’s Proteograph consumables consist of its NP panel and other consumables necessary to assay samples on its SP100 automation instrument. Its SP100 automation instrument is custom-configured liquid handling workstation. The firm's Proteograph Instrument Control Software (PICS) for the SP100 instrument is fixed and designed to its specified workflow.

SEER Intrinsic Value
2.65 USD
Undervaluation 8%
Intrinsic Value
Price

See Also

What is Seer Inc's Accrued Liabilities?
Accrued Liabilities
11.5m USD

Based on the financial report for Dec 31, 2023, Seer Inc's Accrued Liabilities amounts to 11.5m USD.

What is Seer Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
60%

Over the last year, the Accrued Liabilities growth was 14%. The average annual Accrued Liabilities growth rates for Seer Inc have been 28% over the past three years , 60% over the past five years .

Back to Top